Nanobiotix (NASDAQ:NBTX) Trading Up 5.7% - Should You Buy?

Key Points

• Nanobiotix shares rose 5.7% to $40.51, with trading volume about 50% above the average; the stock is up 17.4% recently.
• Analyst sentiment is broadly positive, with a consensus “Moderate Buy” rating and an average price target of $37.33, although targets range from $30 to $46 and one firm maintains a sell rating.
• Nanobiotix is a clinical-stage biotechnology company developing NBTXR3, a nanoparticle-based radiotherapy enhancer, with programs spanning several cancers and CE Mark approval for soft tissue sarcoma in Europe.

Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX - Get Free Report)'s share price was up 5.7% on Monday . The stock traded as high as $40.76 and last traded at $40.51. 114,333 shares traded hands during mid-day trading, an increase of 50% from the average daily volume of 76,429 shares. The stock had previously closed at $38.31.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Weiss Ratings restated a "sell (d-)" rating on shares of Nanobiotix in a research note on Friday, July 17th. HC Wainwright reiterated a "buy" rating on shares of Nanobiotix in a report on Monday, May 18th. UBS Group upped their price target on Nanobiotix from $3.50 to $30.00 and gave the company a "neutral" rating in a research report on Friday, May 1st. Finally, Leerink Partners raised their price objective on Nanobiotix from $37.00 to $46.00 and gave the stock an "outperform" rating in a research note on Thursday, June 4th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $37.33.

Nanobiotix Stock Up 17.4%

The stock has a 50 day simple moving average of $37.82 and a 200 day simple moving average of $34.71.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Millennium Management LLC acquired a new stake in Nanobiotix in the fourth quarter worth $390,000. Royal Bank of Canada boosted its holdings in shares of Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company's stock valued at $61,000 after acquiring an additional 2,500 shares during the period. Finally, Marshall Wace LLP acquired a new position in shares of Nanobiotix during the fourth quarter valued at $220,000. 38.81% of the stock is currently owned by institutional investors.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company's lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source